Cancer: Are herbal medicines ripe for the cancer clinic?

Science Translational Medicine

Volumn 2, Issue 45, 2010, Pages

  Eng, Cathy ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ACHAETE SCUTE LIKE 2 PROTEIN; ANTIBIOTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CHINESE DRUG; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEUCINE RICH REPEAT CONTAINING G PROTEIN COUPLED RECEPTOR 5; LOPERAMIDE; MESSENGER RNA; OLFACTOMEDIN 4; PANITUMUMAB; PHY 906; PLACEBO; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

ABDOMINAL CRAMP; ALTERNATIVE MEDICINE; ANTINEOPLASTIC ACTIVITY; BODY WEIGHT; CANCER CENTER; CELL REGENERATION; CHINESE MEDICINE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; COMPUTER PROGRAM; DIARRHEA; DISEASE MODEL; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG METABOLISM; DRUG POTENTIATION; DRUG QUALITY; ELECTROLYTE DISTURBANCE; FATIGUE; FOOD AND DRUG ADMINISTRATION; GLYCYRRHIZA URALENSIS; HAND FOOT SYNDROME; HERBAL MEDICINE; HUMAN; HYPERTENSION; INTESTINE MUCOSA; JUJUBE; LEUKOPENIA; LIVER CELL CARCINOMA; MASS SPECTROMETRY; MEDICAL DECISION MAKING; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PAEONIA; PAEONIA LACTIFLORA; PANCREAS CANCER; PATIENT CARE; PATIENT MONITORING; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY CONTROL; REPRODUCIBILITY; REVIEW; RISK BENEFIT ANALYSIS; SCUTELLARIA BAICALENSIS; STEM CELL; TREATMENT OUTCOME; TUMOR VOLUME; ANIMAL; DRUG EFFECT; GASTROINTESTINAL TRACT; MOUSE; NEOPLASM; NOTE; PATHOPHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COMPLEMENTARY THERAPIES; GASTROINTESTINAL TRACT; HERBAL MEDICINE; HUMANS; MICE; NEOPLASMS;

EID: 77955866422     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001517     Document Type: Review

References (29)

1. A. Jemal, R. Siegel, J. Xu, E. Ward, Cancer Statistics, CA Cancer J. Clin. 7 July 2010 (10.3322/caac.20073).
2. M. M. Center, A. Jemal, R. A. Smith, E. Ward, Worldwide variations in colorectal cancer. CA Cancer J. Clin. 59, 366-378 (2009).
3. W. Lam, S. Bussom, F. Guan, Z. Jiang, W. Zhang, E. A. Gullen, S.-H. Liu, Y.-C. Cheng, The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. Sci. Transl. Med. 2, 45ra59 (2010).
4. L. B. Saltz, J. V. Cox, C. Blanke, L. S. Rosen, L. Fehrenbacher, M. J. Moore, J. A. Maroun, S. P. Ackland, P. K. Locker, N. Pirotta, G. L. Elfring, L. L. Miller, Irinotecan Study Group, Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 343, 905-914 (2000).
5. D. Cunningham, S. Pyrhönen, R. D. James, C. J. Punt, T. F. Hickish, R. Heikkila, T. B. Johannesen, H. Starkhammar, C. A. Topham, L. Awad, C. Jacques, P. Herait, Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352, 1413-1418 (1998).
6. J. Y. Douillard, D. Cunningham, A. D. Roth, M. Navarro, R. D. James, P. Karasek, P. Jandik, T. Iveson, J. Carmichael, M. Alakl, G. Gruia, L. Awad, P. Rougier, Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355, 1041-1047 (2000).
7. M. L. Rothenberg, N. J. Meropol, E. A. Poplin, E. Van Cutsem, S. Wadler, Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel. J. Clin. Oncol. 19, 3801-3807 (2001).
8. R. M. Logan, R. J. Gibson, J. M. Bowen, A. M. Stringer, S. T. Sonis, D. M. Keefe, Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother. Pharmacol. 62, 33-41 (2008).
9. A. B. Benson 3rd, J. A. Ajani, R. B. Catalano, C. Engelking, S. M. Kornblau, J. A. Martenson Jr., R. McCallum, E. P. Mitchell, T. M. O'Dorisio, E. E. Vokes, S. Wadler, Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J. Clin. Oncol. 22, 2918-2926 (2004).
10. G. Colucci, V. Gebbia, G. Paoletti, F. Giuliani, M. Caruso, N. Gebbia, G. Cartenì, B. Agostara, G. Pezzella, L. Manzione, N. Borsellino, A. Misino, S. Romito, E. Durini, S. Cordio, M. Di Seri, M. Lopez, E. Maiello, S. Montemurro, A. Cramarossa, V. Lorusso, M. Di Bisceglie, M. Chiarenza, M. R. Valerio, T. Guida, V. Leonardi, S. Pisconti, G. Rosati, F. Carrozza, G. Nettis, M. Valdesi, G. Filippelli, S. Fortunato, S. Mancarella, C. Brunetti, Gruppo Oncologico Dell'Italia Meridionale, Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J. Clin. Oncol. 23, 4866-4875 (2005).
11. P. M. Barnes, B. Bloom, R. L. Nahin, Complementary and alternative medicine use among adults and children: United States, 2007. Natl. Health Stat. Report 12, 1-23 (2008).
12. Complementary and Alternative Medicine in the United States, Institute of Medicine (2005); http://www.iom.edu/Reports/2005/Complementary-and-Alternative- Medicine-in-the-United-States.aspx.
13. C. M. Velicer, C. M. Ulrich, Vitamin and mineral supplement use among US adults after cancer diagnosis: A systematic review. J. Clin. Oncol. 26, 665-673 (2008).
14. M. A. Richardson, T. Sanders, J. L. Palmer, A. Greisinger, S. E. Singletary, Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J. Clin. Oncol. 18, 2505-2514 (2000).
15. M. P. Farrell, S. Kummar, Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer. Clin. Colorectal Cancer 2, 253-256 (2003).
16. Shivaani Kummar, Principle Investigator of the study, personal communication.
17. S. Alsamarai, L. Ravage-Mass, K. Kaley, G. Dutschman, W. Zhang, Z. Jiang, S. Liu, Y.C. Cheng, A phase I study of PHY906 as a modulator of irinotecan (CPT-11) in patients with advanced solid tumors. J. Clin. Oncol. 28, e13571 (2010).
18. M. Saif, J. Li, E. Chu, L. Lamb, K. Kaley, K. Elligers, J. Zaoli, S. Bussom, S. Liu, Y. C. Cheng, Phase II study of PHY906 plus capecitabine (CAP) in patients with gemcitabine-refractory advanced pancreatic cancer. Poster presentation at 2010 Gastrointestinal Cancers Symposium. Orlando, Florida, January 2010.
19. C. J. Holmes, L. Lamb, W. Lok, E. Elliger, R. Carbone, K. Keley, F. Lansigan, S. H. Liu, Y. C. Cheng, M. W. Saif, Effect of PHY906 on capecitabine (CAP)-induced diarrhea in patients with GI malignancies. J. Clin. Oncol. 27, e20595 (2010).
20. Y. Yen, S. So, M. Rose, M. W. Saif, E. Chu, S. H. Liu, A. Foo, Z. Jiang, T. Su, Y. C. Cheng, Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma. Anticancer Res. 29, 4083-4092 (2009).
21. S. H. Liu, Z. Jiang, Y. C. Cheng, A chinese medicine formulation, PHY906, can enhance the therapeutic index of CPT-11 and other anti-cancer drugs against cancer in mice. Proc. Am. Assoc. Cancer Res. 42, 458 (2001).
22. L. G. van der Flier, M. E. van Gijn, P. Hatzis, P. Kujala, A. Haegebarth, D. E. Stange, H. Begthel, M. van den Born, V. Guryev, I. Oving, J. H. van Es, N. Barker, P. J. Peters, M. van de Wetering, H. Clevers, Transcription factor achaete scute-like 2 controls intestinal stem cell fate. Cell 136, 903-912 (2009).
23. F. Ye, L. Xui, J. Yi, W. Zhang, D. Y. Zhang, Anticancer activity of Scutellaria baicalensis and its potential mechanism. J. Altern. Complement. Med. 8, 567-572 (2002).
24. H. H. Yoo, J. H. Park, S. W. Kwon, In vitro cytotoxic activity of some Korean medicinal plants on human cancer cell lines: Enhancement in cytotoxicity by heat processing. Phytother. Res. 21, 900-903 (2007).
25. T. Tarragó, N. Kichik, B. Claasen, R. Prades, M. Teixidó, E. Giralt, Baicalin, a prodrug able to reach the CNS, is a prolyl oligopeptidase inhibitor. Bioorg. Med. Chem. 16, 7516-7524 (2008).
26. E. H. Jo, S. H. Kim, J. C. Ra, S. R. Kim, S. D. Cho, J. W. Jung, S. R. Yang, J. S. Park, J. W. Hwang, O. I. Aruoma, T. Y. Kim, Y. S. Lee, K. S. Kang, Chemopreventive properties of the ethanol extract of chinese licorice (Glycyrrhiza uralensis) root: Induction of apoptosis and G1 cell cycle arrest in MCF-7 human breast cancer cells. Cancer Lett. 230, 239-247 (2005).
27. S. H. Lin, S. S. Yang, T. Chau, M. L. Halperin, An unusual cause of hypokalemic paralysis: Chronic licorice ingestion. Am. J. Med. Sci. 325, 153-156 (2003).
28. C. S. Fuchs, J. Marshall, E. Mitchell, R. Wierzbicki, V. Ganju, M. Jeffery, J. Schulz, D. Richards, R. Soufi-Mahjoubi, B. Wang, J. Barrueco, Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C Study. J. Clin. Oncol. 25, 4779-4786 (2007).
29. I thank Richard Lee for his assistance in finding unbiased botanical references.